Genmab — Maj 2021
-
did we know this: KCR Cap
@KcrCap$HALO has patent protection on ENHANZE through 2024 in Europe and 2027 in the US. Royalty rates drop by 50% upon patent expiration, but royalties can still be collected for 10 years following commercial launch https://twitter.com/KcrCap/status/1398041938645995520
-
Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17565
-
this is in Korean, from the Prof who will present on amivantamab at ASCO http://www.dreamdrug.com/Users/News/NewsView.html?ID=276681
-
Langtidsoverlevelse forbedret i MM https://haematologisktidsskrift.dk/sygdomme/myeloma/846-langtidsoverlevelse-vokser-voldsomt-for-myelomatosepatienter.html
-
Bispecific antibodies in review: from cell line development to manufacturing
With the advent of a technology that targets two different epitopes simultaneously, growth in the global bispecific antibody market has accelerated in recent years. Dr Kevin Robinson spoke to Gregory Bleck, Vice President of Research and Development at Catalent Biologics, to discover more about the pros, cons and applications of these innovative therapies
(www.manufacturingchemist.com)
-
@Sukkeralf was there anything interesting in that Lava presentation?
-
Så er vi tilbage til kursen ved årsskiftet
-
Hehe. Det bliver det ikke dårligere af Mogan
-
@StockBull giv gerne et praj inden. Jeg kommer altid forsent
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind